Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 22:55 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2CompletedINTERVENTIONAL

Safety and Efficacy of Liraglutide in Parkinson's Disease

ClinicalTrials.gov · NCT02953665 · Registry updated: 2024-03-07

Condition / research focus: Parkinson Disease
Sponsor: Cedars-Sinai Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2017-04-03. Completion: 2022-08-03 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Victoza, Saxenda
Placebo (drug)

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Cedars Sinai Medical Center
Los Angeles, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

The Use of Liraglutide in Brain Death

ClinicalTrials.gov · NCT03672812 · Registry updated: 2024-03-05

Condition / research focus: Brain Death
Sponsor: Hospital de Clinicas de Porto Alegre
Countries with listed sites: Brazil
Registry dates and results: Start: 2018-09-01. Completion: 2022-02-10 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: placebo

Where the study takes place — 1 listed sites

Hospital Santa Isabel
Blumenau, Santa Catarina, Brazil
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes

ClinicalTrials.gov · NCT02777073 · Registry updated: 2024-02-29

Condition / research focus: Type 1 Diabetes
Sponsor: University at Buffalo
Countries with listed sites: United States
Registry dates and results: Start: 2016-03-01. Completion: 2016-12-31 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Victoza (drug) — also listed as: Liraglutide
Placebo (drug)
Dapagliflozin 10mg Tab (drug) — also listed as: Dapagliflozin

Where the study takes place — 1 listed sites

ECMC Ambulatory Center, 3rd Floor
Buffalo, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Obesity Treatment to Improve Diabetes

ClinicalTrials.gov · NCT05390307 · Registry updated: 2024-02-28

Condition / research focus: Type 1 Diabetes
Sponsor: Dasman Diabetes Institute
Countries with listed sites: Kuwait
Registry dates and results: Start: 2023-04-01. Completion: 2024-01-01 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide / Semaglutide (drug) — also listed as: GLP1RA alone
Dapagliflozin (drug) — also listed as: SGLT2i alone
Liraglutide or Semaglutide / Dapagliflozin (drug) — also listed as: Combination of GLP1RA and SGLT2i
Liraglutide or Semaglutide / Dapagliflozin plus intensive weight loss nutrition (drug) — also listed as: Combination of GLP1RA, SGLT2i and intensive weight loss nutrition
Usual care (other)

Where the study takes place — 1 listed sites

Dasman Diabetes Institute
Kuwait City, Al Asimah, Kuwait
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2TerminatedINTERVENTIONAL

Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates

ClinicalTrials.gov · NCT00609154 · Registry updated: 2024-02-28

Condition / research focus: Type 2 Diabetes
Sponsor: Albert Einstein College of Medicine
Countries with listed sites: United States
Registry dates and results: Start: 2010-08-12. Completion: 2014-05-13 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

glucagon like peptide-1 (drug) — also listed as: incretin
glucose control (dietary_supplement)

Where the study takes place — 1 listed sites

Albert Einstein College of Medicinie
The Bronx, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1

ClinicalTrials.gov · NCT05659368 · Registry updated: 2024-02-22

Condition / research focus: Wolfram Syndrome
Sponsor: Ospedale San Raffaele
Countries with listed sites: Italy
Registry dates and results: Start: 2024-01-01. Completion: 2024-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug)

Where the study takes place — 1 listed sites

IRCCS San Raffaele Scientific Institute
Milan, Italy
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes

ClinicalTrials.gov · NCT03993132 · Registry updated: 2024-02-12

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Boehringer Ingelheim
Countries with listed sites: Denmark
Registry dates and results: Start: 2018-10-01. Completion: 2022-06-16 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Empagliflozin (drug)
Liraglutide (drug)

Where the study takes place — 1 listed sites

Department of Clinical Epidemiology - Aarhus Unversiteteshospital
Aarhus, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide

ClinicalTrials.gov · NCT04081337 · Registry updated: 2024-02-08

Condition / research focus: Obesity
Sponsor: Eli Lilly and Company
Countries with listed sites: United States
Registry dates and results: Start: 2020-07-09. Completion: 2022-05-26 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176
Placebo (drug)

Where the study takes place — 1 listed sites

Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study of Tirzepatide (LY3298176) in Healthy Participants

ClinicalTrials.gov · NCT03375463 · Registry updated: 2024-02-05

Condition / research focus: Healthy
Sponsor: Eli Lilly and Company
Countries with listed sites: United States
Registry dates and results: Start: 2017-12-19. Completion: 2018-12-27 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176
Tirzepatide (drug) — also listed as: LY3298176
Placebo (drug)
Tirzepatide (drug) — also listed as: LY3298176

Where the study takes place — 1 listed sites

Covance
Dallas, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

ClinicalTrials.gov · NCT01509742 · Registry updated: 2024-02-01

Condition / research focus: Diabetes; Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: Germany
Registry dates and results: Start: 2001-04. Completion: 2001-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

liraglutide (drug) — also listed as: NNC 90-1170
placebo (drug)

Where the study takes place — 1 listed sites

Novo Nordisk Investigational Site
Bad Lauterberg im Harz, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease

ClinicalTrials.gov · NCT06236672 · Registry updated: 2024-02-01

Condition / research focus: Type 2 Diabetes; Chronic Kidney Diseases
Sponsor: LMC Diabetes & Endocrinology Ltd.
Countries with listed sites: Canada
Registry dates and results: Start: 2023-02-15. Completion: 2023-11-29 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 receptor agonist (drug)
basal insulin (drug)

Where the study takes place — 1 listed sites

LMC Diabetes & Endocrinology Ltd.
Toronto, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes

ClinicalTrials.gov · NCT06120556 · Registry updated: 2024-01-30

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Countries with listed sites: Italy
Registry dates and results: Start: 2023-06-10. Completion: 2023-10-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 receptor agonist (drug)

Where the study takes place — 1 listed sites

Azienda Ospedaliero-Universitaria Policlinico Bari
Bari, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes

ClinicalTrials.gov · NCT02518945 · Registry updated: 2024-01-24

Condition / research focus: Type 1 Diabetes Mellitus
Sponsor: University at Buffalo
Countries with listed sites: United States
Registry dates and results: Start: 2015-08. Completion: 2016-04 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dapagliflozin (drug) — also listed as: Farxiga
Insulin (drug) — also listed as: Lantus, Levemir, Toujjeo, Humalog , Novolog, Apidra
Liraglutide (drug) — also listed as: Victoza
Dapagliflozin placebo (drug) — also listed as: Placebo

Where the study takes place — 1 listed sites

ECMC Ambulatory Center, 3rd Floor
Buffalo, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Liraglutide in Type 1 Diabetes

ClinicalTrials.gov · NCT01722240 · Registry updated: 2024-01-23

Condition / research focus: Type 1 Diabetes
Sponsor: University at Buffalo
Countries with listed sites: United States
Registry dates and results: Start: 2012-11-01. Completion: 2019-07-29 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide 1.8mg (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Diabetes-Endocrinology Center of WNY
Buffalo, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1UnknownINTERVENTIONAL

The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study

ClinicalTrials.gov · NCT06217848 · Registry updated: 2024-01-23

Condition / research focus: Panhypopituitarism; Craniopharyngioma; Hypothalamic Obesity
Sponsor: Seoul National University Hospital
Countries with listed sites: South Korea
Registry dates and results: Start: 2022-11-28. Completion: 2024-03-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Saxenda (drug)

Where the study takes place — 1 listed sites

Seoul National University Hospital
Seoul, Jongno-gu, South Korea
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)

ClinicalTrials.gov · NCT05024032 · Registry updated: 2024-01-19

Condition / research focus: Obesity; Overweight; Metabolism and Nutrition Disorder
Sponsor: Eli Lilly and Company
Countries with listed sites: China
Registry dates and results: Start: 2021-09-01. Completion: 2022-12-27 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176
Placebo (drug)

Where the study takes place — 29 listed sites

Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
The First Affiliated Hospital Chongqing Medical University
Chongqing, Chongqing Municipality, China
Site recruitment: Not reported
Zhujiang Hospital
Guangzhou, Guangdong, China
Site recruitment: Not reported
Shenzhen Second People's Hospital
Shenzhen, Guangdong, China
Site recruitment: Not reported
The First Hospital of Qinhuangdao
Qinhuangdao, Hebei, China
Site recruitment: Not reported
The Fourth Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Site recruitment: Not reported
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang, Henan, China
Site recruitment: Not reported
The Second Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Site recruitment: Not reported
The First Affiliated Hospital of Nanhua University
Hengyang, Hunan, China
Site recruitment: Not reported
Changzhou No.2 People's Hospital
Changzhou, Jiangsu, China
Site recruitment: Not reported
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Site recruitment: Not reported
Nanjing Medical University - Nanjing Jiangning Hospital
Nanjing, Jiangsu, China
Site recruitment: Not reported
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China
Site recruitment: Not reported
Wuxi People's Hospital
Wuxi, Jiangsu, China
Site recruitment: Not reported
The Second Hospital of Jilin University
Changchun, Jilin, China
Site recruitment: Not reported
Siping Central People's Hospital
Siping, Jilin, China
Site recruitment: Not reported
Jinan Central Hospital
Jinan, Shandong, China
Site recruitment: Not reported
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Huadong Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Shanghai Hospital of Traditional Chinese Medicine
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Qingpu Branch of Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
The First Affiliated Hospital of Xi'an Medical University
Xi’an, Shanxi, China
Site recruitment: Not reported
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Site recruitment: Not reported
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Site recruitment: Not reported
The First People's Hospital of Hangzhou
Hangzhou, Zhejiang, China
Site recruitment: Not reported
Huzhou Central Hospital
Huzhou, Zhejiang, China
Site recruitment: Not reported
Ningbo First Hospital
Ningbo, Zhejiang, China
Site recruitment: Not reported
The Fifth People's Hospital of Shanghai
Shanghai, China
Site recruitment: Not reported
Shanghai Minhang District Central Hospital
Shanghai, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery

ClinicalTrials.gov · NCT06201819 · Registry updated: 2024-01-18

Condition / research focus: Weight Loss; Bariatric Surgery Candidate; Obesity, Morbid
Sponsor: Hospital Civil Juan I. Menchaca
Countries with listed sites: Mexico
Registry dates and results: Start: 2022-12-18. Completion: 2023-05-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide injection (drug)

Where the study takes place — 1 listed sites

Departamento de Cirugia Bariatrica y Metabolica del Hsopital Civil Dr. Juan I. Menchaca
Guadalajara, Jalisco, Mexico
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

ClinicalTrials.gov · NCT02759107 · Registry updated: 2024-01-16

Condition / research focus: Healthy; Type 2 Diabetes Mellitus (T2DM)
Sponsor: Eli Lilly and Company
Countries with listed sites: Singapore · United States
Registry dates and results: Start: 2016-05-11. Completion: 2017-06-26 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176
Placebo (drug)
Dulaglutide (drug) — also listed as: Trulicity®

Where the study takes place — 2 listed sites

Miami Research Associates
South Miami, Florida, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Singapore, Singapore
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2UnknownINTERVENTIONAL

Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue

ClinicalTrials.gov · NCT05751720 · Registry updated: 2024-01-12

Condition / research focus: Non-Alcoholic Fatty Liver Disease; Non-alcoholic Steatohepatitis; Type 2 Diabetes; Liver Fat
Sponsor: Dr Adnan Agha
Countries with listed sites: United Arab Emirates
Registry dates and results: Start: 2023-10-01. Completion: 2025-02 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GIP/GLP-1a (drug)

Where the study takes place — 1 listed sites

Internal Medicine, College of Medicine and Health Sciences
Al Ain City, Abu Dhabi Emirate, United Arab Emirates
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide

ClinicalTrials.gov · NCT04407234 · Registry updated: 2024-01-08

Condition / research focus: Overweight; Obesity; Diabetes Mellitus, Type 2
Sponsor: Eli Lilly and Company
Countries with listed sites: United States
Registry dates and results: Start: 2020-09-15. Completion: 2021-01-07 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176
Acetaminophen (drug)

Where the study takes place — 1 listed sites

Clinical Pharmacology of Miami
Hialeah, Florida, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 22:55 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2CompletedINTERVENTIONAL

Safety and Efficacy of Liraglutide in Parkinson's Disease

ClinicalTrials.gov · NCT02953665 · Registry updated: 2024-03-07

Condition / research focus: Parkinson Disease
Sponsor: Cedars-Sinai Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2017-04-03. Completion: 2022-08-03 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Victoza, Saxenda
Placebo (drug)

Where the study takes place — 1 listed sites

Cedars Sinai Medical Center
Los Angeles, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

The Use of Liraglutide in Brain Death

ClinicalTrials.gov · NCT03672812 · Registry updated: 2024-03-05

Condition / research focus: Brain Death
Sponsor: Hospital de Clinicas de Porto Alegre
Countries with listed sites: Brazil
Registry dates and results: Start: 2018-09-01. Completion: 2022-02-10 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: placebo

Where the study takes place — 1 listed sites

Hospital Santa Isabel
Blumenau, Santa Catarina, Brazil
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes

ClinicalTrials.gov · NCT02777073 · Registry updated: 2024-02-29

Condition / research focus: Type 1 Diabetes
Sponsor: University at Buffalo
Countries with listed sites: United States
Registry dates and results: Start: 2016-03-01. Completion: 2016-12-31 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Victoza (drug) — also listed as: Liraglutide
Placebo (drug)
Dapagliflozin 10mg Tab (drug) — also listed as: Dapagliflozin

Where the study takes place — 1 listed sites

ECMC Ambulatory Center, 3rd Floor
Buffalo, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Obesity Treatment to Improve Diabetes

ClinicalTrials.gov · NCT05390307 · Registry updated: 2024-02-28

Condition / research focus: Type 1 Diabetes
Sponsor: Dasman Diabetes Institute
Countries with listed sites: Kuwait
Registry dates and results: Start: 2023-04-01. Completion: 2024-01-01 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide / Semaglutide (drug) — also listed as: GLP1RA alone
Dapagliflozin (drug) — also listed as: SGLT2i alone
Liraglutide or Semaglutide / Dapagliflozin (drug) — also listed as: Combination of GLP1RA and SGLT2i
Liraglutide or Semaglutide / Dapagliflozin plus intensive weight loss nutrition (drug) — also listed as: Combination of GLP1RA, SGLT2i and intensive weight loss nutrition
Usual care (other)

Where the study takes place — 1 listed sites

Dasman Diabetes Institute
Kuwait City, Al Asimah, Kuwait
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2TerminatedINTERVENTIONAL

Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates

ClinicalTrials.gov · NCT00609154 · Registry updated: 2024-02-28

Condition / research focus: Type 2 Diabetes
Sponsor: Albert Einstein College of Medicine
Countries with listed sites: United States
Registry dates and results: Start: 2010-08-12. Completion: 2014-05-13 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

glucagon like peptide-1 (drug) — also listed as: incretin
glucose control (dietary_supplement)

Where the study takes place — 1 listed sites

Albert Einstein College of Medicinie
The Bronx, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1

ClinicalTrials.gov · NCT05659368 · Registry updated: 2024-02-22

Condition / research focus: Wolfram Syndrome
Sponsor: Ospedale San Raffaele
Countries with listed sites: Italy
Registry dates and results: Start: 2024-01-01. Completion: 2024-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug)

Where the study takes place — 1 listed sites

IRCCS San Raffaele Scientific Institute
Milan, Italy
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes

ClinicalTrials.gov · NCT03993132 · Registry updated: 2024-02-12

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Boehringer Ingelheim
Countries with listed sites: Denmark
Registry dates and results: Start: 2018-10-01. Completion: 2022-06-16 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Empagliflozin (drug)
Liraglutide (drug)

Where the study takes place — 1 listed sites

Department of Clinical Epidemiology - Aarhus Unversiteteshospital
Aarhus, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide

ClinicalTrials.gov · NCT04081337 · Registry updated: 2024-02-08

Condition / research focus: Obesity
Sponsor: Eli Lilly and Company
Countries with listed sites: United States
Registry dates and results: Start: 2020-07-09. Completion: 2022-05-26 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176
Placebo (drug)

Where the study takes place — 1 listed sites

Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study of Tirzepatide (LY3298176) in Healthy Participants

ClinicalTrials.gov · NCT03375463 · Registry updated: 2024-02-05

Condition / research focus: Healthy
Sponsor: Eli Lilly and Company
Countries with listed sites: United States
Registry dates and results: Start: 2017-12-19. Completion: 2018-12-27 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176
Tirzepatide (drug) — also listed as: LY3298176
Placebo (drug)
Tirzepatide (drug) — also listed as: LY3298176

Where the study takes place — 1 listed sites

Covance
Dallas, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

ClinicalTrials.gov · NCT01509742 · Registry updated: 2024-02-01

Condition / research focus: Diabetes; Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: Germany
Registry dates and results: Start: 2001-04. Completion: 2001-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

liraglutide (drug) — also listed as: NNC 90-1170
placebo (drug)

Where the study takes place — 1 listed sites

Novo Nordisk Investigational Site
Bad Lauterberg im Harz, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease

ClinicalTrials.gov · NCT06236672 · Registry updated: 2024-02-01

Condition / research focus: Type 2 Diabetes; Chronic Kidney Diseases
Sponsor: LMC Diabetes & Endocrinology Ltd.
Countries with listed sites: Canada
Registry dates and results: Start: 2023-02-15. Completion: 2023-11-29 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 receptor agonist (drug)
basal insulin (drug)

Where the study takes place — 1 listed sites

LMC Diabetes & Endocrinology Ltd.
Toronto, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes

ClinicalTrials.gov · NCT06120556 · Registry updated: 2024-01-30

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Countries with listed sites: Italy
Registry dates and results: Start: 2023-06-10. Completion: 2023-10-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 receptor agonist (drug)

Where the study takes place — 1 listed sites

Azienda Ospedaliero-Universitaria Policlinico Bari
Bari, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes

ClinicalTrials.gov · NCT02518945 · Registry updated: 2024-01-24

Condition / research focus: Type 1 Diabetes Mellitus
Sponsor: University at Buffalo
Countries with listed sites: United States
Registry dates and results: Start: 2015-08. Completion: 2016-04 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dapagliflozin (drug) — also listed as: Farxiga
Insulin (drug) — also listed as: Lantus, Levemir, Toujjeo, Humalog , Novolog, Apidra
Liraglutide (drug) — also listed as: Victoza
Dapagliflozin placebo (drug) — also listed as: Placebo

Where the study takes place — 1 listed sites

ECMC Ambulatory Center, 3rd Floor
Buffalo, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Liraglutide in Type 1 Diabetes

ClinicalTrials.gov · NCT01722240 · Registry updated: 2024-01-23

Condition / research focus: Type 1 Diabetes
Sponsor: University at Buffalo
Countries with listed sites: United States
Registry dates and results: Start: 2012-11-01. Completion: 2019-07-29 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide 1.8mg (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Diabetes-Endocrinology Center of WNY
Buffalo, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1UnknownINTERVENTIONAL

The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study

ClinicalTrials.gov · NCT06217848 · Registry updated: 2024-01-23

Condition / research focus: Panhypopituitarism; Craniopharyngioma; Hypothalamic Obesity
Sponsor: Seoul National University Hospital
Countries with listed sites: South Korea
Registry dates and results: Start: 2022-11-28. Completion: 2024-03-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Saxenda (drug)

Where the study takes place — 1 listed sites

Seoul National University Hospital
Seoul, Jongno-gu, South Korea
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)

ClinicalTrials.gov · NCT05024032 · Registry updated: 2024-01-19

Condition / research focus: Obesity; Overweight; Metabolism and Nutrition Disorder
Sponsor: Eli Lilly and Company
Countries with listed sites: China
Registry dates and results: Start: 2021-09-01. Completion: 2022-12-27 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176
Placebo (drug)

Where the study takes place — 29 listed sites

Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
The First Affiliated Hospital Chongqing Medical University
Chongqing, Chongqing Municipality, China
Site recruitment: Not reported
Zhujiang Hospital
Guangzhou, Guangdong, China
Site recruitment: Not reported
Shenzhen Second People's Hospital
Shenzhen, Guangdong, China
Site recruitment: Not reported
The First Hospital of Qinhuangdao
Qinhuangdao, Hebei, China
Site recruitment: Not reported
The Fourth Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Site recruitment: Not reported
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang, Henan, China
Site recruitment: Not reported
The Second Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Site recruitment: Not reported
The First Affiliated Hospital of Nanhua University
Hengyang, Hunan, China
Site recruitment: Not reported
Changzhou No.2 People's Hospital
Changzhou, Jiangsu, China
Site recruitment: Not reported
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Site recruitment: Not reported
Nanjing Medical University - Nanjing Jiangning Hospital
Nanjing, Jiangsu, China
Site recruitment: Not reported
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China
Site recruitment: Not reported
Wuxi People's Hospital
Wuxi, Jiangsu, China
Site recruitment: Not reported
The Second Hospital of Jilin University
Changchun, Jilin, China
Site recruitment: Not reported
Siping Central People's Hospital
Siping, Jilin, China
Site recruitment: Not reported
Jinan Central Hospital
Jinan, Shandong, China
Site recruitment: Not reported
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Huadong Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Shanghai Hospital of Traditional Chinese Medicine
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Qingpu Branch of Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
The First Affiliated Hospital of Xi'an Medical University
Xi’an, Shanxi, China
Site recruitment: Not reported
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Site recruitment: Not reported
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Site recruitment: Not reported
The First People's Hospital of Hangzhou
Hangzhou, Zhejiang, China
Site recruitment: Not reported
Huzhou Central Hospital
Huzhou, Zhejiang, China
Site recruitment: Not reported
Ningbo First Hospital
Ningbo, Zhejiang, China
Site recruitment: Not reported
The Fifth People's Hospital of Shanghai
Shanghai, China
Site recruitment: Not reported
Shanghai Minhang District Central Hospital
Shanghai, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery

ClinicalTrials.gov · NCT06201819 · Registry updated: 2024-01-18

Condition / research focus: Weight Loss; Bariatric Surgery Candidate; Obesity, Morbid
Sponsor: Hospital Civil Juan I. Menchaca
Countries with listed sites: Mexico
Registry dates and results: Start: 2022-12-18. Completion: 2023-05-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide injection (drug)

Where the study takes place — 1 listed sites

Departamento de Cirugia Bariatrica y Metabolica del Hsopital Civil Dr. Juan I. Menchaca
Guadalajara, Jalisco, Mexico
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

ClinicalTrials.gov · NCT02759107 · Registry updated: 2024-01-16

Condition / research focus: Healthy; Type 2 Diabetes Mellitus (T2DM)
Sponsor: Eli Lilly and Company
Countries with listed sites: Singapore · United States
Registry dates and results: Start: 2016-05-11. Completion: 2017-06-26 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176
Placebo (drug)
Dulaglutide (drug) — also listed as: Trulicity®

Where the study takes place — 2 listed sites

Miami Research Associates
South Miami, Florida, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Singapore, Singapore
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2UnknownINTERVENTIONAL

Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue

ClinicalTrials.gov · NCT05751720 · Registry updated: 2024-01-12

Condition / research focus: Non-Alcoholic Fatty Liver Disease; Non-alcoholic Steatohepatitis; Type 2 Diabetes; Liver Fat
Sponsor: Dr Adnan Agha
Countries with listed sites: United Arab Emirates
Registry dates and results: Start: 2023-10-01. Completion: 2025-02 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GIP/GLP-1a (drug)

Where the study takes place — 1 listed sites

Internal Medicine, College of Medicine and Health Sciences
Al Ain City, Abu Dhabi Emirate, United Arab Emirates
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide

ClinicalTrials.gov · NCT04407234 · Registry updated: 2024-01-08

Condition / research focus: Overweight; Obesity; Diabetes Mellitus, Type 2
Sponsor: Eli Lilly and Company
Countries with listed sites: United States
Registry dates and results: Start: 2020-09-15. Completion: 2021-01-07 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176
Acetaminophen (drug)

Where the study takes place — 1 listed sites

Clinical Pharmacology of Miami
Hialeah, Florida, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →